<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086146</url>
  </required_header>
  <id_info>
    <org_study_id>2020-63</org_study_id>
    <secondary_id>2020-A03384-35</secondary_id>
    <nct_id>NCT05086146</nct_id>
  </id_info>
  <brief_title>Prognostic Impact of Cardiac Imaging During Suspected Immune Checkpoint Inhibitor Myocarditis</brief_title>
  <acronym>IMMUNOIMAGING</acronym>
  <official_title>Prognostic Impact of Cardiac Imaging During Suspected Immune Checkpoint Inhibitor Myocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It consists of evaluating the advantage of routine detection of phIGFBP-1 to reduce the total&#xD;
      duration of hospitalization for patients with a risk of preterm labor before 32 weeks of&#xD;
      gestation without increasing the number of preterm labour.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient with a risk of preterm labor (ultrasound cervical length &lt; 25 mm +/- described or&#xD;
      recorded uterine contractions) before 32 weeks of gestation will be hospitalized to receive&#xD;
      tocolytic drugs and antenatal corticosteroid therapy according to the investigators gold&#xD;
      standard protocol. After 48 hours, the participants will be assessed by examination, external&#xD;
      tocodynamometry and the measure of cervical length by ultrasound. Stabilized patients will be&#xD;
      included and randomized into 2 groups of 210 patients each. The first group &quot;A&quot; will benefit&#xD;
      from the standard protocol (extended hospitalization of 2 or 4 days according to the clinical&#xD;
      and ultrasound assessment); whereas the second group, &quot;B&quot;, will have the benefit of the&#xD;
      detection of phIGFBP-1.If the result proves negative, patients could be discharged early at&#xD;
      day 2. In the case of a positive result, patients will follow the standard procedure because&#xD;
      of the low positive predictive value of the test. The main outcome is the total duration of&#xD;
      hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence rate of the composite end point</measure>
    <time_frame>6-month</time_frame>
    <description>including cardiovascular death, acute heart failure, cardiogenic shock, cardiac arrest, sustained ventricular tachycardia, ventricular fibrillation, 2nd-degree (except Mobitz 1) or 3rd-degree atrioventricular block.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of all-cause death</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocarditis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all patients with suspected myocarditis on ICIs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients affiliated to the French social security system will be eligible, after&#xD;
        signing a consent form, and presenting the following criteria&#xD;
&#xD;
          -  Introduction within the last 3 months of at least one of the following ICIs:&#xD;
             nivolumab, pembrolizumab, cemiplimab, avelumab, atezolizumab, ipilimumab,&#xD;
             tremelimumab, durvalumab.&#xD;
&#xD;
          -  Suspicion of myocarditis defined by the presence of at least one of the following&#xD;
             criteria adapted from the European Society of Cardiology guidelines:&#xD;
&#xD;
               -  Symptomatic patients (chest pain, dyspnea, palpitations, syncope/lipothymia)&#xD;
                  within 7 days of ICI administration&#xD;
&#xD;
               -  New ECG abnormality (ST-segment elevation, ST-segment undershift, arrhythmia,&#xD;
                  conductive disturbances, T-wave inversion)&#xD;
&#xD;
               -  Elevation of troponin above the 99th percentile of the laboratory reference value&#xD;
                  or, if troponin is already elevated before treatment, an increase of more than&#xD;
                  30% of the baseline value&#xD;
&#xD;
               -  Recent LVEF decline or recent LV contraction abnormality on a TTE&#xD;
&#xD;
          -  Patient has given no objection&#xD;
&#xD;
        Translated with www.DeepL.com/Translator (free version)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Major under guardianship or curatorship&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patient not covered by a social security plan&#xD;
&#xD;
          -  Hemodynamic or rhythmic instability&#xD;
&#xD;
          -  Estimation of glomerular filtration rate by the MDRD formula &lt;30ml/min/1.73m2&#xD;
&#xD;
          -  Implantable equipment that does not allow for cMRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François CREMIEUX</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DEHARO PIERRE</last_name>
    <phone>(0)4 91 96 86 83</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre.deharo@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>assistance publique hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>deharo francois</last_name>
      <phone>(0)4 91 96 86 83</phone>
      <email>francois.deharo@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

